STOCK TITAN

SNGX Schedule 13G: Intracoastal and Individuals Report 4.99% Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Soligenix Schedule 13G summary: This filing reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC (the Reporting Persons) each may be deemed to beneficially own 446,408 shares of Soligenix common stock, representing 4.99% of the class as of the close of business on October 1, 2025. The filing explains ownership arises from warrants issued under a Securities Purchase Agreement dated September 25, 2025 and details earlier potential beneficial ownership figures tied to issuance and exercise of three warrants and a contemplated issuance of 425,000 shares to Intracoastal at closing. Blocker provisions in the warrants limit exercise to remain at or below specified ownership thresholds.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Passive holdings reported at 4.99% following an SPA; warrants with blocker provisions constrain exercised ownership.

The Schedule 13G discloses passive beneficial ownership by two individuals and an affiliated LLC each holding 446,408 shares, equal to 4.99% of Soligenix on the stated basis. The filing ties these holdings to warrants and a securities purchase agreement executed September 25, 2025 and notes blocker provisions that prevent exercise beyond specified ownership caps. For investors, this indicates disclosure and compliance with SEC passive investor reporting rather than an active attempt to influence control.

TL;DR: Ownership is reported as passive and limited by warrant blocker clauses, reducing governance/control implications.

The report specifies that Intracoastal and the two named individuals are filing under Schedule 13G, asserting the securities are not held to change or influence issuer control. The document details how blocker provisions in three warrants limit potential conversion and help maintain ownership below control thresholds (0.99% or 4.99% as applicable). This filing therefore signals adherence to reporting rules and limited governance impact from these holdings.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Mitchell P. Kopin
Signature:/s/ Mitchell P. Kopin
Name/Title:Mitchell P. Kopin
Date:10/01/2025
Daniel B. Asher
Signature:/s/ Daniel B. Asher
Name/Title:Daniel B. Asher
Date:10/01/2025
INTRACOASTAL CAPITAL, LLC
Signature:/s/ Mitchell P. Kopin
Name/Title:Mitchell P. Kopin, Manager
Date:10/01/2025
Exhibit Information

Exhibit 1 - Joint Filing Agreement

FAQ

What percentage of Soligenix (SNGX) does each reporting person beneficially own?

Each reporting person is reported to beneficially own 446,408 shares, representing 4.99% of the common stock as of October 1, 2025.

Why does the filing reference warrants and a Securities Purchase Agreement dated September 25, 2025?

The reported holdings arise from shares issuable and warrants issued under the Securities Purchase Agreement (SPA) dated September 25, 2025, which established issuance and warrant terms disclosed in the filing.

Do the reporting persons claim they seek to influence control of Soligenix?

No. The certifications state the securities were not acquired and are not held to change or influence control of the issuer, consistent with a Schedule 13G passive filing.

What are the blocker provisions mentioned in the filing?

Blocker provisions in the warrants prevent exercise to the extent such exercise would cause beneficial ownership to exceed specified limits (e.g., 0.99% or 4.99%), as described in the filing.

How many shares could reporting persons have been deemed to own without blocker provisions?

The filing states that without the blocker provisions the Reporting Persons may have been deemed to beneficially own up to 1,113,125 shares in one scenario and 558,125 shares in another scenario described.
Soligenix Inc

NASDAQ:SNGX

SNGX Rankings

SNGX Latest News

SNGX Latest SEC Filings

SNGX Stock Data

14.52M
9.65M
0.02%
4.43%
4.63%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON